908244-98-4

Usage

Uses

Used in Pharmaceutical Industry:
4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER is used as a chemical intermediate for the synthesis of piperidine derivatives in the pharmaceutical industry. These derivatives are valuable for their potential as inhibitors and therapeutic agents, contributing to the development of new medications and treatments for various diseases and conditions.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-METHYL-PIPERIDINE-3-CARBOXYLIC ACID METHYL ESTER is utilized as a key component in the creation of various piperidine-based compounds. Its role in these syntheses allows for the exploration of new chemical pathways and the discovery of novel compounds with potential applications in various industries.

Upstream product

• 3222-50-2 4-methylnicotinic acid 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 33402-75-4 4-methylnicotinic acid methyl ester 

Downstream Products

• 1201192-62-2 1-(tert-butyl) 3-methyl 4-methylpiperidine-1,3-dicarboxylate 
• 1271810-25-3 trans 1-(tert-butoxycarbonyl)-4-methylpiperidine-3-carboxylic acid 
• 1207853-61-9 trans-racemic tert-butyl 3-amino-4-methylpiperidine-1-carboxylate 
• 1009376-52-6 1-(tert-butoxycarbonyl)-4-methylpiperidine-3-carboxylic acid 

Relevant academic research and scientific papers

9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

[1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND

The present invention relates to a novel [l,2,4]triazolo[l,5-a]pyrimidin-yl derivative of formula (1) as inhibitor of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compound, to processes for preparing such compound and compositions, and to the use of such compound and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

BRUTON'S TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The invention provides a class of inhibitors, packaged pharmaceuticals comprising such inhibitors, and uses of the inhibitors in treating, or the manufacturing medicaments for treating central nervous system disorders, including depression, anxiety, sleep